Toothfairy EIS Hero

Toothfairy EIS

This offer is closed

Want to know when this offer opens?

Register your interest

About this deal What to expect post-investment
This is a co-investment alongside Haatch Ventures LLP, which has reviewed the opportunity and selected it for its Haatch Direct service. Please read the offer documents carefully. Haatch Ventures, the EIS fund manager, will produce initial and ongoing shareholder documents.

This overview is provided to make it easier for you to form your own view about the opportunity.

Fast-growing, £2.6 million revenue “dentist via an app” for employees, with clients including HM Government, Rolls-Royce and Sainsbury’s

30 million people struggle to find fast and affordable access to dentistry in the UK, it’s estimated. So, dental issues may go undetected or untreated – thereby worsening and becoming a more expensive problem for both patients and their employers. 23 million working days are missed annually due to dental problems.

To address this, celebrity dentists Dr. Deepak Aulak and Dr. Kian Dhinsa founded Toothfairy – the world’s first digital dentist on-demand.

The award-winning, patented Toothfairy app connects patients with a dentist directly for consultations, treatment, clinic referrals, virtual exams and prescriptions. Toothfairy's proprietary AI and Image Recognition technology can help dentists detect and track patients’ dental disease. It also includes a 24/7 helpline and access to an emergency dental team.

To date, Toothfairy is contracted to cover over 3 million patients across the UK, with over 7-in-10 of all dental issues solved in-app.

Tested in the NHS, Toothfairy has secured regulatory approval – and is the UK’s first health-regulated CQC dental app. Its proprietary dental AI, Ora, has been trained by licensed dentists over 10,000+ hours.

Patients may access Toothfairy’s dental app as a direct customer – or be offered it through their employer or health insurer.

In 2024, Toothfairy generated £2.6 million total revenue, and has contracted over £1 million in annual recurring revenue (ARR) with B2B clients. With strong revenue growth, the Company has reached profitability in some recent quarters, and reports a strong pipeline with insurers, banks and travel insurance providers.

Now to help grow its B2B offering, enhance its AI technology, scale further in the UK/US market, the Company is seeking to raise Series A funding of £6 million.

Over £5 million has been committed so far, including from existing backers Haatch, Ada Ventures and Slingshot Ventures. Wealth Club has an exclusive allocation of £500k, investing on the same terms (£90.72 per share). 

Haatch believes the investment could potentially deliver a return in the region of 5x before EIS tax relief but after fees in five years – high risk and not guaranteed. Haatch has previously backed Toothfairy via its EIS fund.

Please carefully read all investment documents prepared by the Company and Haatch to form your own view.

Important: The information on this website is for experienced investors. It is not advice nor a research or personal recommendation to invest. If you’re unsure, please seek advice. Investments are for the long term. They are high risk and illiquid and can fall as well as rise in value, so you could get back less than you invest.

Haatch's interview

Toothfairy at a glance: hear it from the founder/CEO

Play Video: Toothfairy at a glance

Toothfairy’s B2B2C business model

Patients may access Toothfairy’s dentistry as a direct customer – or be offered it through their employer’s or insurer’s app.

Insurers like Aviva (currently in pilot), Canada Life and Unum have offered Toothfairy to their members, and customised it with features like dentist chat, symptom checker and a claims portal.

Likewise, over 1,500 employers (HM Government, Rolls-Royce, Sainsbury’s, DHL for example) have offered Toothfairy as a dental benefit.

Through its various channels, Toothfairy currently has a reach of more than 3 million members and has garnered over 1.1k reviews on Trustpilot, with an average rating of 4.8/5 stars.

Toothfairy estimates its addressable market is worth $12 billion in the UK and $36 billion in the US (2023).

Awards and recognition

  • Management believes Toothfairy to be the world's smartest teledentistry app, using patented technology
  • Named one of the Top 100 fastest-growing companies in the UK by Sifted (Financial Times)
  • Awarded Healthcare Solution of the Year 2023 by Health Tech Digital
  • Winner of the App of the Year at the Dental Industry Award
  • Highly Commended for High Tech Launch of the Year
  • Winner of Outstanding Added Value Provider – Cover Awards 2024
Toothfairy offers a high percentage of diagnosis and subsequent prescriptions while also helping facilitate convenient appointments with local dentists if and when required. The UK is experiencing a real dentistry challenge and we believe Toothfairy are well placed to play a lead role in addressing that challenge.

B2B customer, insurance provider Canada Life

Risks – important

This is a single company offer with no diversification. It involves investing in an early-stage, loss-making business, which is by nature high risk and prone to failure. There is a risk that the capital raised may not be sufficient to achieve the Company’s objectives. You could lose all the amount you invest.

Like all investments available through Wealth Club, it is only for experienced investors happy to make their own investment decisions without advice.

There is no ready market for unlisted EIS shares: they are illiquid and hard to sell and value. There will need to be an exit for you to receive a realised return on your investment.

Exits are likely to take considerably longer than the three-year minimum EIS holding period; equally, an exit within three years could impact tax relief. The value of tax benefits depends on circumstances and tax rules can change.

Before you invest, please carefully read the Information Memorandum which contains further details on the considerable risks – alongside the Wealth Club Risks and Commitments.

Please note: the Company is expected to be included in the current tranches of Haatch's funds. 

Structure and fees

Investors will invest in Toothfairy only via the Haatch EIS fund, an Alternative Investment Fund. The fund is managed by Haatch Ventures LLP, whilst Apex Unitas Limited (Mainspring) will act as the custodian and administrator. Wealth Club Limited is the introducer of this offer.

The investment is expected to be EIS-qualifying – not guaranteed.
Wealth Club investors will invest at the same price and on the same terms as the other investors in this round.

All the services Wealth Club and, where applicable, its subsidiaries provide are governed by the Terms and Conditions of the Wealth Club Services.

Fees

A set-up and management fee of 6.5% will be payable to Haatch. This fee will be deducted from your subscription and will reduce the amount invested and on which tax relief can be claimed. 

Haatch will also receive a performance fee on returns over £1 per £1 invested: 25% on proceeds between 1x and 5x, 30% on proceeds over 5x. 

Haatch will share these fees 60/40 with Wealth Club. This will not involve any additional costs to investors or the company. 

The fees and charges above are stated exclusive of VAT, which applies in some cases, as determined by the manager. Please check the VAT position carefully in the offer documents.

This financial promotion has been communicated and approved by Wealth Club Ltd on 24 April 2025

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – investments. You should base your investment decision on the offer documents and ensure you have read and fully understand them before investing. The information on this webpage is a marketing communication. It is not advice or a personal or research recommendation to buy any of the investments mentioned, nor does it include any opinion as to the present or future value or price of these investments. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.

opens in new window